Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Accountprinceon Jul 23, 2021 4:32pm
198 Views
Post# 33597436

RE:RE:FDA appointed DSMB leads don't get 400K 46 cent options...

RE:RE:FDA appointed DSMB leads don't get 400K 46 cent options...Buy low...sell high. So if insiders sell low they suffer the same as Joe Q public so I see where Seto feels there no benefit in a low price in that circumstance.

But, hypothetically, if insiders can buy low when the share price happens to drop or President's List purchasers buy low (F&F?) or options exercised when price is low so capital gains treatment then there is a big benefit for all those fortunate few in those hypothetical situations.

But eventually when the dust settles from this ten million disastrous and avoidable pileup and the innocent bystanders have healed their diluted wounds the damage perhaps will be soothed as the price heads up.  Hopefully  the 90% earmarked for the US does indeed get sold in the US to people that will promote in the US.  And if no other planned disasters exist perhaps attention can be focused on the Catalysts as put forward in the last presentation to shareholders.

Then ultimately all of us sell at a high price.  I do recall someone shared recently that Seto said anyone that sells now will really regret that decision.  And I think MM also shared that he thought Seto dropped a 3 to 5 month time frame during the AGM.  Hope that's all accurate and not out of context.



<< Previous
Bullboard Posts
Next >>